<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f1 { font-family:ff0,sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff1; src: url("1.ttf"); }
#f2 { font-family:ff1,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff2; src: url("2.ttf"); }
#f3 { font-family:ff2,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f4 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f5 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f6 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff6; src: url("6.ttf"); }
#f7 { font-family:ff6,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff7; src: url("7.ttf"); }
#f8 { font-family:ff7,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f9 { font-family:ff8,serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff9; src: url("9.ttf"); }
#f10 { font-family:ff9,monospace; font-weight:bold; font-style:normal; }
@font-face { font-family: ff10; src: url("10.ttf"); }
#f11 { font-family:ff10,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff11; src: url("11.ttf"); }
#f12 { font-family:ff11,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="842" src="page1.png">
<div class="txt" style="position:absolute; left:478px; top:72px;"><span id="f2" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">기업 </span><span id="f1" style="font-size:12px;vertical-align:baseline;color:rgba(0,0,0,1);">Note</span></div>
<div class="txt" style="position:absolute; left:497px; top:92px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">2017.9.18</span></div>
<div class="txt" style="position:absolute; left:190px; top:161px;"><span id="f11" style="font-size:20px;vertical-align:baseline;color:rgba(0,160,198,1);">삼성바이오로직스(207940)</span></div>
<div class="txt" style="position:absolute; left:28px; top:192px;"><span id="f2" style="font-size:18px;vertical-align:baseline;color:rgba(0,0,0,1);">매수(유지)</span></div>
<div class="txt" style="position:absolute; left:190px; top:193px;"><span id="f12" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오시밀러 두번째 first-mover 장착</span></div>
<div class="txt" style="position:absolute; left:28px; top:223px;"><span id="f2" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">목표주가: 400,000원(상향)</span></div>
<div class="txt" style="position:absolute; left:28px; top:252px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">Stock Data</span></div>
<div class="txt" style="position:absolute; left:28px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">KOSPI(9/15)</span></div>
<div class="txt" style="position:absolute; left:157px; top:267px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">2,386</span></div>
<div class="txt" style="position:absolute; left:28px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주가(9/15)</span></div>
<div class="txt" style="position:absolute; left:149px; top:278px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">326,500</span></div>
<div class="txt" style="position:absolute; left:28px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">시가총액(십억원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:290px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">21,603</span></div>
<div class="txt" style="position:absolute; left:28px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">발행주식수(백만)</span></div>
<div class="txt" style="position:absolute; left:166px; top:301px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">66</span></div>
<div class="txt" style="position:absolute; left:28px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">52주 최고/최저가(원)</span></div>
<div class="txt" style="position:absolute; left:123px; top:313px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">326,500/142,000</span></div>
<div class="txt" style="position:absolute; left:28px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">일평균거래대금(6개월, 백만원)</span></div>
<div class="txt" style="position:absolute; left:153px; top:324px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">69,264</span></div>
<div class="txt" style="position:absolute; left:28px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">유동주식비율/외국인지분율(%)</span></div>
<div class="txt" style="position:absolute; left:149px; top:335px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">21.8/9.8</span></div>
<div class="txt" style="position:absolute; left:28px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">주요주주(%) 삼성물산 외 3 인</span></div>
<div class="txt" style="position:absolute; left:160px; top:347px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">75.0</span></div>
<div class="txt" style="position:absolute; left:189px; top:228px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">삼성의 최초 Herceptin 바이오시밀러, 내년 초 유럽시장 출시 유력</span></div>
<div class="txt" style="position:absolute; left:189px; top:243px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">9월 15일 삼성바이오로직스의 자회사 바이오에피스는 EMA(유럽의약품청) 산하</span></div>
<div class="txt" style="position:absolute; left:189px; top:257px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">CHMP(약물사용자문위원회)로부터 Herceptin의 바이오시밀러 온트루잔트(Ontruzant)에</span></div>
<div class="txt" style="position:absolute; left:189px; top:272px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">대해 긍정의견을 받았다. 이에 따라 바이오에피스는 11월경 품목허가를 받고 내년 1분기</span></div>
<div class="txt" style="position:absolute; left:189px; top:286px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">중 유럽시장에 온트루잔트를 출시할 수 있을 전망이다. 마케팅은 Merck가 담당한다. 이로</span></div>
<div class="txt" style="position:absolute; left:189px; top:300px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">써 바이오에피스는 베네팔리(Enbrel 바이오시밀러)에 이어 두번째 first-mover 바이오시</span></div>
<div class="txt" style="position:absolute; left:189px; top:314px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">밀러를 보유하게 됐으며 Herceptin 시장침투에 있어 경쟁사 대비 우위를 점할 수 있을 것</span></div>
<div class="txt" style="position:absolute; left:189px; top:328px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">으로 기대한다. Herceptin은 Roche가 개발한 유방암 치료제로 2016년 글로벌 매출 70억</span></div>
<div class="txt" style="position:absolute; left:189px; top:343px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">달러(8조원), 유럽 매출 19억유로(2.4조원)에 달하는 블록버스터 제품이다.</span></div>
<div class="txt" style="position:absolute; left:28px; top:377px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">주가상승률</span></div>
<div class="txt" style="position:absolute; left:28px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">절대주가(%)</span></div>
<div class="txt" style="position:absolute; left:28px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">상대주가(%p)</span></div>
<div class="txt" style="position:absolute; left:92px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">1개월</span></div>
<div class="txt" style="position:absolute; left:95px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">20.5</span></div>
<div class="txt" style="position:absolute; left:95px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">18.3</span></div>
<div class="txt" style="position:absolute; left:125px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">6개월</span></div>
<div class="txt" style="position:absolute; left:128px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">88.2</span></div>
<div class="txt" style="position:absolute; left:128px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">76.3</span></div>
<div class="txt" style="position:absolute; left:154px; top:389px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">12개월</span></div>
<div class="txt" style="position:absolute; left:164px; top:399px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:164px; top:409px;"><span id="f5" style="font-size:7px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:28px; top:427px;"><span id="f5" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PBR 추이</span></div>
<div class="txt" style="position:absolute; left:29px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">7.0</span></div>
<div class="txt" style="position:absolute; left:46px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(배)</span></div>
<div class="txt" style="position:absolute; left:29px; top:456px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">6.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:469px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">5.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:482px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">4.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:494px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">3.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:507px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">2.0</span></div>
<div class="txt" style="position:absolute; left:29px; top:519px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">1.0</span></div>
<div class="txt" style="position:absolute; left:75px; top:442px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">12MF PBR (좌)</span></div>
<div class="txt" style="position:absolute; left:139px; top:441px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">(천원)</span></div>
<div class="txt" style="position:absolute; left:166px; top:444px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">400</span></div>
<div class="txt" style="position:absolute; left:75px; top:451px;"><span id="f8" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스 주가 (우)</span></div>
<div class="txt" style="position:absolute; left:166px; top:455px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">350</span></div>
<div class="txt" style="position:absolute; left:166px; top:466px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">300</span></div>
<div class="txt" style="position:absolute; left:166px; top:477px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">250</span></div>
<div class="txt" style="position:absolute; left:166px; top:488px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">200</span></div>
<div class="txt" style="position:absolute; left:166px; top:499px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">150</span></div>
<div class="txt" style="position:absolute; left:166px; top:510px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">100</span></div>
<div class="txt" style="position:absolute; left:166px; top:521px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">50</span></div>
<div class="txt" style="position:absolute; left:29px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0.0</span></div>
<div class="txt" style="position:absolute; left:166px; top:532px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">0</span></div>
<div class="txt" style="position:absolute; left:35px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Oct-14</span></div>
<div class="txt" style="position:absolute; left:76px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Oct-15</span></div>
<div class="txt" style="position:absolute; left:116px; top:537px;"><span id="f3" style="font-size:4px;vertical-align:baseline;color:rgba(0,0,0,1);">Oct-16</span></div>
<div class="txt" style="position:absolute; left:28px; top:546px;"><span id="f5" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">자료: WISEfn 컨센서스</span></div>
<div class="txt" style="position:absolute; left:189px; top:370px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">이미 검증된 유럽시장에서 성공 가능성을 보여준 항암제 바이오시밀러</span></div>
<div class="txt" style="position:absolute; left:189px; top:385px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오시밀러의 확산이 다소 더딘 미국과는 달리 유럽시장은 바이오시밀러의 처방이 활발</span></div>
<div class="txt" style="position:absolute; left:189px; top:399px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">하게 이루어지고 있다. 셀트리온의 램시마(Remicade 바이오시밀러)는 출시 3년만인 2016</span></div>
<div class="txt" style="position:absolute; left:189px; top:414px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">년 유럽시장에서 40%의 점유율을 확보했다. 또한 2016년 2월 유럽에서 출시한 바이오에</span></div>
<div class="txt" style="position:absolute; left:189px; top:428px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">피스의 베네팔리(Enbrel 바이오시밀러)는 올해 2분기 유럽에서 8,870만달러의 매출을 올</span></div>
<div class="txt" style="position:absolute; left:189px; top:442px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">리며 15%의 점유율을 달성한 것으로 추정되는 만큼 유럽에서 바이오시밀러는 30% 이상</span></div>
<div class="txt" style="position:absolute; left:189px; top:456px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">의 가격 경쟁력을 바탕으로 빠르게 확산되고 있다. 한편 자가면역치료제가 아닌 생명과</span></div>
<div class="txt" style="position:absolute; left:189px; top:470px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">직결된 항암제도 바이오시밀러가 성공적으로 안착할 수 있을지에 대한 우려가 존재했다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:485px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">그러나 올해 4월 셀트리온이 유럽시장에 출시한 혈액암 치료제 트룩시마(Rituxan 바이오</span></div>
<div class="txt" style="position:absolute; left:189px; top:499px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">시밀러)가 출시 3개월만에 일부 국가에서 30%의 점유율을 확보하면서 항암제 바이오시밀</span></div>
<div class="txt" style="position:absolute; left:189px; top:513px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">러에 대한 성공 가능성을 엿볼 수 있었다. 따라서 유럽에서 출시될 바이오에피스의 유방</span></div>
<div class="txt" style="position:absolute; left:189px; top:527px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">암 치료제 온트루잔트 역시 출시 직후 빠른 점유율 확대가 기대된다.</span></div>
<div class="txt" style="position:absolute; left:189px; top:555px;"><span id="f6" style="font-size:10px;vertical-align:baseline;color:rgba(0,160,198,1);">가파르게 개선될 현금흐름을 고려하여 목표주가를 40만원으로 상향</span></div>
<div class="txt" style="position:absolute; left:189px; top:570px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">삼성바이오로직스에 대해 매수 투자의견을 유지하고 2018년부터 가파르게 개선될 FCF(잉</span></div>
<div class="txt" style="position:absolute; left:189px; top:584px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">여현금흐름)를 고려하여 목표주가를 기존 35만원에서 40만원으로 14% 상향한다. 삼성바</span></div>
<div class="txt" style="position:absolute; left:189px; top:598px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">이오로직스는 2분기 마지막 영업적자를 뒤로하고 3분기부터는 흑자기조를 이어가는 한편</span></div>
<div class="txt" style="position:absolute; left:189px; top:612px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">바이오에피스는 세계시장에 신제품을 지속적으로 출시해 나갈 전망이다. 2018년 이후</span></div>
<div class="txt" style="position:absolute; left:189px; top:627px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">CMO 세계 1위 등극이 예정돼 있고 바이오시밀러를 넘어 신약개발업체로 변모해 나갈 삼</span></div>
<div class="txt" style="position:absolute; left:189px; top:641px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">성바이오로직스에 대해 긴 호흡에서 매수를 권고한다.</span></div>
<div class="txt" style="position:absolute; left:29px; top:731px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">진홍국</span></div>
<div class="txt" style="position:absolute; left:29px; top:743px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">hg.jin@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:29px; top:761px;"><span id="f5" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">정은영</span></div>
<div class="txt" style="position:absolute; left:28px; top:771px;"><span id="f3" style="font-size:8px;vertical-align:baseline;color:rgba(0,0,0,1);">eunice.jung@truefriend.com</span></div>
<div class="txt" style="position:absolute; left:228px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">매출액 영업이익 순이익</span></div>
<div class="txt" style="position:absolute; left:336px; top:694px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EPS 증감률 EBITDA PER </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">EV/EBITDA </span><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">PBR ROE DY</span></div>
<div class="txt" style="position:absolute; left:223px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(십억원) (십억원) (십억원)</span></div>
<div class="txt" style="position:absolute; left:338px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(원)</span></div>
<div class="txt" style="position:absolute; left:367px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(%) (십억원)</span></div>
<div class="txt" style="position:absolute; left:428px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x)</span></div>
<div class="txt" style="position:absolute; left:457px; top:706px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(x) (x) (%) (%)</span></div>
<div class="txt" style="position:absolute; left:189px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2015A</span></div>
<div class="txt" style="position:absolute; left:240px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">91</span></div>
<div class="txt" style="position:absolute; left:265px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(204) 1,905</span></div>
<div class="txt" style="position:absolute; left:345px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:374px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">- (162)</span></div>
<div class="txt" style="position:absolute; left:432px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:461px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:485px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">- 68.7</span></div>
<div class="txt" style="position:absolute; left:534px; top:717px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2016A</span></div>
<div class="txt" style="position:absolute; left:236px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">295</span></div>
<div class="txt" style="position:absolute; left:269px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(30)</span></div>
<div class="txt" style="position:absolute; left:300px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(177) (1,558)</span></div>
<div class="txt" style="position:absolute; left:368px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">30 NM 320.6 4.9 (5.2)</span></div>
<div class="txt" style="position:absolute; left:534px; top:728px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2017F</span></div>
<div class="txt" style="position:absolute; left:236px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">418</span></div>
<div class="txt" style="position:absolute; left:277px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">8</span></div>
<div class="txt" style="position:absolute; left:300px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">(127) (1,926)</span></div>
<div class="txt" style="position:absolute; left:368px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:402px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">70 NM 307.9 6.0 (3.3)</span></div>
<div class="txt" style="position:absolute; left:534px; top:740px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2018F</span></div>
<div class="txt" style="position:absolute; left:236px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">578</span></div>
<div class="txt" style="position:absolute; left:270px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">105</span></div>
<div class="txt" style="position:absolute; left:304px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">528 1,423</span></div>
<div class="txt" style="position:absolute; left:368px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">NM</span></div>
<div class="txt" style="position:absolute; left:399px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">184 229.5 115.9 5.4 14.0</span></div>
<div class="txt" style="position:absolute; left:534px; top:751px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
<div class="txt" style="position:absolute; left:189px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">2019F</span></div>
<div class="txt" style="position:absolute; left:236px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">944</span></div>
<div class="txt" style="position:absolute; left:270px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">324</span></div>
<div class="txt" style="position:absolute; left:304px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">270 4,083 187.0</span></div>
<div class="txt" style="position:absolute; left:399px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">430 80.0 49.0 5.0 6.5</span></div>
<div class="txt" style="position:absolute; left:534px; top:762px;"><span id="f8" style="font-size:6px;vertical-align:baseline;color:rgba(0,0,0,1);">-</span></div>
</body>
</html>
